The effects of the β-lactam antibiotic, ceftriaxone, on forepaw stepping and l-DOPA-induced dyskinesia in a rodent model of Parkinson's disease

Psychopharmacology

Volumn 231, Issue 12, 2014, Pages 2405-2415

  Kelsey, John E ^a   Neville, Caroline ^a  

^a BATES COLLEGE   (United States)

Author keywords

6 OHDA; AIMs; Ceftriaxone; Dihydrokainate; Dyskinesia; GLT 1; LID; Parkinson's; Stepping

Indexed keywords

CEFTRIAXONE; DIHYDROKAINIC ACID; LEVODOPA; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; VESICULAR GLUTAMATE TRANSPORTER 1; ANTIINFECTIVE AGENT; ANTIPARKINSON AGENT; CENTRAL NERVOUS SYSTEM AGENTS; EXCITATORY AMINO ACID TRANSPORTER 2; KAINIC ACID; SLC1A2 PROTEIN, RAT;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; BODY WEIGHT; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; DYSKINESIA; LEG MOVEMENT; MALE; MEDIAL FOREBRAIN BUNDLE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RODENT MODEL; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; FORELIMB; LONG EVANS RAT; METABOLISM; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIPARKINSON AGENTS; CEFTRIAXONE; CENTRAL NERVOUS SYSTEM AGENTS; DYSKINESIA, DRUG-INDUCED; EXCITATORY AMINO ACID TRANSPORTER 2; FORELIMB; KAINIC ACID; LEVODOPA; MALE; MEDIAL FOREBRAIN BUNDLE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS, LONG-EVANS;

EID: 84902178855     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3400-6     Document Type: Article

References (35)

1. Anderson CM, Swanson RA (2000) Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia 32:1-14
2. Berry JD, Shefner JM, Conwit R, Schoenfeld D, Keroack M, Felsenstein D, Krivickas L, David WS, Vriesendorp F, Pestronk A, Caress JB, Katz J, Simpson E, Rosenfeld J, Pascuzzi R, Glass J, Rezania K, Rothstein JD, Greenblatt DJ, Cudkowicz ME, Northeast ALS Consortium (2013) Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One 8:e61177. doi: 10.1371/journal.pone.0061177;10.1371/journal.pone. 0061177
3. Blanchet PJ, Konitsiotis S, Chase TN (1998) Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 13:798-802. doi: 10.1002/mds.870130507
4. Chang JW, Wachtel SR, Young D, Kang UJ (1999) Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88:617-628
5. Chu K, Lee ST, Sinn DI, Ko SY, Kim EH, Kim JM, Kim SJ, Park DK, Jung KH, Song EC, Lee SK, Kim M, Roh JK (2007) Pharmacological induction of ischemic tolerance by glutamate transporter-1 (EAAT2) upregulation. Stroke 38:177-182. doi: 10.1161/01.STR.0000252091.36912.65
6. Cui C, Cui Y, Gao J, Sun L, Wang Y, Wang K, Li R, Tian Y, Song S, Cui J (2013) Neuroprotective effect of ceftriaxone in a rat model of traumatic brain injury. Neurol Sci. doi: 10.1007/s10072-013-1585-4
7. Duty S (2012) Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease. CNS Drugs 26:1017-1032. doi: 10.1007/s40263-012-0016-z;10.1007/s40263- 012-0016-z
8. Elahi B, Phielipp N, Chen R (2012) N-Methyl-d-aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. Can J Neurol Sci 39:465-472
9. 1 antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. Behav Brain Res 203:304-307. doi: 10.1016/j.bbr.2009.04.035
10. 1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat. Psychopharmacology 201:529-539. doi: 10.1007/s00213-008-1319-0
11. Kelsey JE, Mague SD, Pijanowski RS, Harris RC, Kleckner NW, Matthews RT (2004) NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats. Psychopharmacology 175:179-188. doi: 10.1007/s00213-004-1799-5
12. Kobylecki C, Cenci MA, Crossman AR, Ravenscroft P (2010) Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease. J Neurochem 114:499-511. doi: 10.1111/j.1471-4159.2010.06776.x;10.1111/j.1471-4159.2010.06776.x
13. Lamb HM, Ormrod D, Scott LJ, Figgitt DP (2002) Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. Drugs 62:1041-1089
14. Leung TC, Lui CN, Chen LW, Yung WH, Chan YS, Yung KK (2012) Ceftriaxone ameliorates motor deficits and protects dopaminergic neurons in 6-hydroxydopamine-lesioned rats. ACS Chem Neurosci 3:22-30. doi: 10.1021/cn200072h;10.1021/cn200072h
15. Löschmann PA, Lange KW, Kunow M, Rettig KJ, Jahnig P, Honore T, Turski L, Wachtel H, Jenner P, Marsden CD (1991) Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with l-dopa in models of Parkinson's disease. J Neural Transm Parkinsons Dis Dementia Sect 3:203-213
16. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15:120-132
17. Miller BR, Dorner JL, Shou M, Sari Y, Barton SJ, Sengelaub DR, Kennedy RT, Rebec GV (2008) Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 153:329-337. doi: 10.1016/j. neuroscience.2008.02.004
18. Mouradian MM, Heuser IJ, Baronti F, Chase TN (1990) Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 27:18-23. doi: 10.1002/ana.410270105
19. Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maneuf Y, Hille C, Brotchie JM, Crossman AR (2000) Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 165:136-142. doi: 10.1006/exnr.2000.7444
20. Oh JD, Russell DS, Vaughan CL, Chase TN (1998) Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and l-DOPA administration. Brain Res 813:150-159
21. Papa SM, Chase TN (1996) Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 39:574-578. doi: 10.1002/ana.410390505
22. Paxinos G, Watson C (2006) The rat brain in stereotaxic coordinates. Academic Press, San Diego
23. Pines G, Danbolt NC, Bjoras M, Zhang Y, Bendahan A, Eide L, Koepsell H, Storm-Mathisen J, Seeberg E, Kanner BI (1992) Cloning and expression of a rat brain l-glutamate transporter. Nature 360:464-467. doi: 10.1038/360464a0
24. Rabey JM, Nissipeanu P, Korczyn AD (1992) Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm Park Dis Dement Sect 4:277-282
25. Rasmussen BA, Baron DA, Kim JK, Unterwald EM, Rawls SM (2011) β-Lactam antibiotic produces a sustained reduction in extracellular glutamate in the nucleus accumbens of rats. Amino Acids 40:761-764. doi: 10.1007/s00726-010-0589-0;10.1007/s00726-010-0589-0
26. Rebec GV (2013) Dysregulation of corticostriatal ascorbate release and glutamate uptake in transgenic models of Huntington's disease. Antioxid Redox Signal. doi: 10.1089/ars.2013.5387
27. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB (2005) β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433:73-77. doi: 10.1038/nature03180
28. Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, Kanai Y, Hediger MA, Wang Y, Schielke JP, Welty DF (1996) Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16:675-686
29. Sgambato-Faure V, Cenci MA (2012) Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson' disease. Prog Neuro 96:69-86. doi: 10.1016/j.pneurobio.2011.10.005
30. Snow BJ, Macdonald L, Mcauley D, Wallis W (2000) The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 23:82-85
31. Tanaka K (2005) Antibiotics rescue neurons from glutamate attack. Trends Mol Med 11:259-262. doi: 10.1016/j.molmed.2005.04.002
32. Thone-Reineke C, Neumann C, Namsolleck P, Schmerbach K, Krikov M, Schefe JH, Lucht K, Hortnagl H, Godes M, Muller S, Rumschussel K, Funke-Kaiser H, Villringer A, Steckelings UM, Unger T (2008) The β-lactam antibiotic, ceftriaxone, dramatically improves survival, increases glutamate uptake and induces neurotrophins in stroke. J Hypertens 26:2426-2435. doi: 10.1097/HJH.0b013e328313e40
33. Verma R, Mishra V, Sasmal D, Raghubir R (2010) Pharmacological evaluation of glutamate transporter 1 (GLT-1) mediated neuroprotection following cerebral ischemia/reperfusion injury. Eur J Pharmacol 638:65-71. doi: 10.1016/j.ejphar.2010.04.021
34. Weiss JL, Ng LK, Chase TN (1971) Long-lasting dyskinesia induced by levodopa. Lancet 1:1016-1017
35. Winkler C, Kirik D, Bjorklund A, Cenci MA (2002) l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10:165-186